Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell 5Recurrence 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Immunoblastic Lymphadenopathy 2Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Hodgkin Disease 1Head and Neck Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × duvelisib × 1 year × Clear all
NCT05976997 2026-05-18

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

Huazhong University of Science and Technology

Phase 2 Recruiting
36 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06522737 2026-04-06

TERZO

SecuraBio

Phase 3 Recruiting
124 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡